TW239869B - - Google Patents

Download PDF

Info

Publication number
TW239869B
TW239869B TW081105670A TW81105670A TW239869B TW 239869 B TW239869 B TW 239869B TW 081105670 A TW081105670 A TW 081105670A TW 81105670 A TW81105670 A TW 81105670A TW 239869 B TW239869 B TW 239869B
Authority
TW
Taiwan
Prior art keywords
compound
annexin
conjugate
item
patent application
Prior art date
Application number
TW081105670A
Other languages
English (en)
Chinese (zh)
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of TW239869B publication Critical patent/TW239869B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW081105670A 1991-05-09 1992-07-17 TW239869B (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69736491A 1991-05-09 1991-05-09

Publications (1)

Publication Number Publication Date
TW239869B true TW239869B (fr) 1995-02-01

Family

ID=24800848

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081105670A TW239869B (fr) 1991-05-09 1992-07-17

Country Status (5)

Country Link
EP (1) EP0538459A4 (fr)
JP (1) JPH05508664A (fr)
CA (1) CA2086437A1 (fr)
TW (1) TW239869B (fr)
WO (1) WO1992019279A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE254631T1 (de) * 1993-12-07 2003-12-15 Neorx Corp Pretargeting verfahren und mitteln
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
EP0743861B1 (fr) * 1994-01-24 2003-04-16 Neorx Corporation Annexines marquees isotopiquement
EP0765166B1 (fr) * 1994-06-16 2003-05-21 Neorx Corporation Conjugues radiomarques d'annexine-galactose
CA2185349C (fr) * 1994-06-16 2010-04-20 John M. Reno Conjugues radiomarques d'annexine-galactose
JPH10512852A (ja) * 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
CA2206274C (fr) * 1994-12-07 2009-06-30 Neorx Corporation Conjugues groupes annexine-galactose radiomarques
DE69838811T2 (de) 1997-04-30 2008-10-30 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Verfahren zur darstellung von abgestorbenen zellen in-vivo
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
FR2784106B1 (fr) 1998-10-02 2002-04-19 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
JP2004528025A (ja) * 2001-02-21 2004-09-16 サーロメッド・インコーポレーテッド 修飾されたアネキシン蛋白質及び血栓症を防ぐための方法
CA2443314C (fr) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Imagerie in-vivo de l'apoptose
WO2002080754A2 (fr) 2001-04-03 2002-10-17 Theseus Imaging Corporation Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2856069A1 (fr) * 2003-06-10 2004-12-17 Bionexis Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
AU8492991A (en) * 1990-10-04 1992-04-28 New England Deaconess Hospital Corporation Soluble thrombogenesis inhibitor conjugates

Also Published As

Publication number Publication date
CA2086437A1 (fr) 1992-11-10
EP0538459A1 (fr) 1993-04-28
EP0538459A4 (en) 1993-06-16
WO1992019279A1 (fr) 1992-11-12
JPH05508664A (ja) 1993-12-02

Similar Documents

Publication Publication Date Title
TW239869B (fr)
US5632986A (en) Phospholipid-targeted thrombolytic agents
TW538048B (en) A soluble derivative of a soluble polypeptide and its use
RU2466141C2 (ru) МОДИФИЦИРОВАННЫЙ КОАГУЛИРУЮЩИЙ ФАКТОР VIIa С ПРОДЛЕННЫМ ВРЕМЕНЕМ ПОЛУЖИЗНИ
TW587081B (en) Vitamin K-dependent polypeptide with enhanced membrane binding affinity, protein C or activated protein C polypeptide, and pharmaceutical composition thereof
US5011686A (en) Thrombus specific conjugates
CN101405017A (zh) 具有磷脂酰丝氨酸结合结构域的嵌合蛋白
JPH05508766A (ja) フィブリン結合ドメインポリペプチド及びその使用，並びにその製造方法
KR101492422B1 (ko) 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
MX2010010759A (es) Mutantes de estreptocinasa y sus formas covalentemente modificadas.
JP2015501137A (ja) 止血を調節するための組成物および方法
JP2007528847A (ja) 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
EA005944B1 (ru) Фибринолитически активный полипептид
US5474766A (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
JPH05506646A (ja) ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法
JPH10505502A (ja) 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
JPH04505554A (ja) 可溶性トロンボモジュリン類似体
WO2002014369A9 (fr) Polypeptides du domaine d5 humain de production de kinine s
JP3095771B2 (ja) ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
JPS63269980A (ja) 新規化合物、その製法及びそれを含む医薬組成物
WO2023275024A1 (fr) Administration sous-cutanée de facteur ix à sécurité renforcée
EP2504027A1 (fr) Accélération de la cicatrisation par un inhibiteur tissulaire de métalloprotéinases (timp) lié à des ancres glycosylphosphatidylinositols (gpi)
MIRZA jllafiter of $ l| ilofl (oplip
AU2013202563A1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides